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Background: Metformin, an oral anti-hyperglycemic drug which inhibits mitochondrial
complex I and oxidative phosphorylation has been reported to correlate with improved
outcomes in head and neck squamous cell carcinoma (HNSCC) and other cancers. This
effect is postulated to occur through disruption of tumor-driven metabolic and immune
dysregulation in the tumormicroenvironment (TME).We report new findings on the impact
of metformin on the tumor and immune elements of the TME from a clinical trial of
metformin in HNSCC.
Methods: Human papilloma virus—(HPV–) tobacco+ mucosal HNSCC samples
(n = 12) were compared to HPV+ oropharyngeal squamous cell carcinoma (OPSCC)
samples (n = 17) from patients enrolled in a clinical trial. Apoptosis in tumor samples
pre- and post-treatment with metformin was compared by deoxynucleotidyl transferase
dUTP nick end labeling (TUNEL) assay. Metastatic lymph nodes with extra-capsular
extension (ECE) in metformin-treated patients (n = 7) were compared to archival lymph
node samples with ECE (n = 11) for differences in immune markers quantified by digital
image analysis using co-localization and nuclear algorithms (PD-L1, FoxP3, CD163,
CD8).
Results: HPV–, tobacco + HNSCC (mean 1 13.7/high power field) specimens
had a significantly higher increase in apoptosis compared to HPV+ OPSCC
specimens (mean 1 5.7/high power field) (p < 0.001). Analysis of the stroma at
the invasive front in ECE nodal specimens from both HPV—HNSCC and HPV+
OPSCC metformin treated specimens showed increased CD8+ effector T cell infiltrate
(mean 22.8%) compared to archival specimens (mean 10.7%) (p = 0.006). Similarly,
metformin treated specimens showed an increased FoxP3+ regulatory T cell infiltrate
(mean 9%) compared to non-treated archival specimens (mean 5%) (p = 0.019).
Curry et al. Metformin in HNSCC
Conclusions: This study presents novel data demonstrating that metformin differentially
impacts HNSCC subtypes with greater apoptosis in HPV—HNSCC compared to HPV+
OPSCC. Moreover, we present the first in vivo human evidence that metformin may
also trigger increased CD8+ Teff and FoxP3+ Tregs in the TME, suggesting an
immunomodulatory effect in HNSCC. Further research is necessary to assess the effect
of metformin on the TME of HNSCC.
Keywords: head and neck cancer, squamous cell carcinoma, metformin, tumor microenvironment, immune
infiltrate, HPV, tumor metabolism
INTRODUCTION
Metformin is an oral biguanide anti-hyperglycemic and the
most commonly prescribed medication for type 2 diabetes
mellitus. Interestingly, data suggests that metformin may have
antineoplastic properties as well. Retrospective epidemiologic
analyses, while limited due to the number of confounders, have
also shown a decreased incidence of HNSCC in patients taking
metformin (1, 2). Diabetics treated with metformin have a cancer
risk reduction of approximately 40% compared to diabetics not
treated with metformin (3, 4). Other studies have also shown
a reduction in the frequency of cancer with metformin use
(5). Evans et al. reported that the risk of subsequent cancer
diagnosis was reduced in patients with type 2 diabetes who
receivedmetformin (with an odds ratio of 0.85 for anymetformin
exposure versus no metformin exposure) (6).
Extensive preclinical data support the effectiveness of
metformin as an antineoplastic agent (7–10). In HNSCC
specifically, metformin inhibits proliferation of carcinoma cells
and induces apoptosis in vitro and in vivo, in addition to reducing
colony formation with cell cycle arrest in vitro (7). In vitro and
in vivo animal models have also shown that metformin can
prevent the conversion of premalignant oral lesions to squamous
cell carcinoma. Metformin has been shown to reduce the size and
numbers of oral tumors inmouse models treated with 4NQO and
halt the progression of potential premalignant lesions (11). This
study, by Vitale-Cross et al. not only showed a decrease in the
total number of oral lesions in animals treated with metformin
compared to control, but also showed almost complete absence
of transformation to squamous cell carcinoma.
Additional preclinical data was recently published suggesting
that there may be a synergy between immune-oncology agents
and metformin. Scharping et al. demonstrated a substantial
increase in response rate in themurine B16melanomamodel and
MC38 colon adenocarcinoma model with combination therapy
utilizing PD-1 axis inhibition in combination with metformin
(12). PD-1 blockade alone in B16 resulted in no reduction of
tumor burden and 20% reduction of tumor burden in MC38
mice. Metformin alone demonstrated no reduction in tumor
burden. However, combination therapy of PD-1 blockade and
metformin resulted in tumor regression in 70% of B16 mice
and 80% of MC38 mice. Moreover, CD8+ effector T cells
(Teff) showed increased production of effector cytokines in the
combination therapy group, suggesting a direct impact on the
immune TME. The interplay of the immune antitumor response
and metabolism in the TME is an area of active investigation, as
dysregulated metabolism in immune cells critically alters effector
function. Immune cell metabolic exhaustion is believed to be
one of the key factors contributing to suppressed cytotoxic CD8
effector function in the TME (13). Further, T cells undergo
reversible anergy when they are placed in a low pH environment,
characteristic of many cancers and particularly HNSCC (14,
15).
To further explore the impact of metformin in HNSCC,
we performed a window of opportunity trial using metformin
alone prior to definitive surgical resection in HNSCC patients.
This study showed increase in the percent of samples showing
caveolin1 (CAV1) expression in cancer associated fibroblasts
(CAFs) from an average of 17–65% of the samples tested
(16). This “rescue” of CAV1, a key regulator of mitochondrial
metabolism, in CAFs suggests that metformin may induce a
partial reversal of the metabolic phenotype of CAFs (17). We
demonstrated a significant increase in tumor cell apoptosis
in tumor cells after treatment with metformin by TUNEL
(terminal deoxyribonucleotidyl transferase mediated dUTP-
digoxigenin nick end labeling) assay (p < 0.001). Here we
report results of novel sub-analyses on cancer cell apoptosis in
HPV+ and HPV– groups and alterations in the immune TME
mediated by metformin and an exploration of the impact of
metformin treatment on the immune TME of involved lymph
nodes.
MATERIALS AND METHODS
Subjects
The metformin clinical trial specimens were primary tumor
and lymph node samples obtained from a surgical trial in
HNSCC patients. This study was carried out in accordance
with the recommendations of Internal Review Board (IRB) of
Thomas Jefferson University with written informed consent
from all subjects. All subjects gave written informed consent in
accordance with the Declaration of Helsinki. The protocol was
approved by the Internal Review Board of Thomas Jefferson
University. The trial was conducted with IRB approval and
design, enrollment, and demographics are as described in
detail elsewhere (16). (https://www.clinicaltrials.gov/ct2/show/
NCT02083692). The flow for the trial is shown in Figure 1.
Briefly, paired pre- and post-operative primary tumor tissue
samples were compared for each patient. Patients included
had a new, pathologically-confirmed diagnosis of HNSCC.
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Demographics are shown in Table 1. Enrolled patients received
metformin titrated up every 3 days up to a standard anti-diabetic
dose of 1000mg twice daily for up to 28 days prior to surgery
with only specimens from patients with ≥9 days (range 9–24,
mean 13.6 days) of therapy being analyzed. Patients received
no additional cancer treatment while metformin was being
administered. Of the 50 HNSCC patients enrolled, 39 completed
the course of at least 9 days and had evaluable data and pre and
post treatment specimens; of these 17 were HPV+ oropharyngeal
squamous cell carcinoma (OPSCC) and 22 were HPV– HNSCC.
Primary tumor samples were categorized according to HPV and
smoking status. HPV status was demonstrated by p16 staining
and subsequent in situ hybridization for HPV16 and 18. The
pre-treatment and post-treatment specimens were compared by
terminal deoxynucleotidyl transferase dUTP nick end labeling
(TUNEL) assay for tumor cell apoptosis. For the current TUNEL
comparison, HPV+ OPSCC samples (n= 17) were compared to
HPV–, tobacco + HNSCC samples (n = 12). To assess immune
elements of the TME, analysis of CD8, FoxP3, PD-L1, and CD163
staining intensity was carried out via digital image analysis using
Aperio (Leica Biosystems,Wetzlar, Germany) co-localization and
nuclear algorithms for assessment of intensity and quantification.
FFPE lymph node specimens from patients on the trial with nodal
metastasis demonstrating ECE (n= 7) were compared to archival
FFPE ECE lymph node specimens (n = 11) from patients not
receiving metformin either on trial or as a part of their medical
record prior to surgery. Archival specimens were obtained with
IRB approval.
Immunohistochemistry
Tissue sections (4µm) for IHC analysis were dewaxed,
rehydrated through graded ethanols, and antigen retrieval
was performed on the Ventana Discovery ULTRA staining
platform using Discovery CCI (Ventana cat#950-500) for a
total application time of 64min. Secondary immunostaining
used a Horseradish Peroxidase (HRP) multimer cocktail
(Ventana cat#760-500) and immune complexes were visualized
using the ultraView Universal DAB (diaminobenzidine
tetrahydrochloride) Detection Kit (Ventana cat#760-500). Slides
were then washed with a Tris based reaction buffer (Ventana
cat#950-300) and stained with Hematoxylin II (Ventana cat
#790-2208) for 8min. The CD8 antibody (CONFIRM Anti-CD8
SP57 Rabbit Monoclonal Primary antibody) and PD-L1 antibody
(VENTANA PD-L1 (SP263) Rabbit Monoclonal Primary
Antibody were obtained from Roche-Ventana, Tucson,AZ,
USA). The FoxP3 (SP97) antibody was obtained from Spring
Biosciences (Pleasanton, CA). The CD163 antibody (MRQ-
26 mouse monoclonal antibody) was obtained from Cell
Marque (Rocklin, CA, USA). Sections were counterstained with
hematoxylin.
For quantification of apoptotic cells the TUNEL-based
ApopTag Peroxidase in situ Apoptosis Detection Kit (Millipore
Sigma Lifesciences, Burlington, MA) was used. The number of
nuclei with TUNEL staining per high power field (hpf) was
averaged over five HPFs in each specimen, and the mean was
reported. For each sample, scores from two pathologists were
averaged to yield a final score for statistical analysis.
TABLE 1 | Demographics for clinical trial patients.
Demographics
Age 61.7 (35–80)
Gender 28 m/11 f
Days on metformin 13.56 (9–24)
Anatomic subsite
Oral cavity 13 (33.3%) Oropharynx 21 (53.8%)
Skin 1 (2.6%) HPV+ OPSCC 17/21 (81.0%)
Larynx 3 (7.7%) Hypopharynx 1 (2.6%)
Staging (AJCC 2017)
T stage N stage
Tis 1 (2.6%) N0 16 (41.0%)
T1 8 (20.5%) N1 3 (7.7%)
T2 19 (48.7%) N2a 5 (12.8%)
T3 3 (7.7%) N2b 12 (30.8%)
T4a 8 (20.5%) N2c 0 (0%)
T4b 0 (0%) N3 3 (7.7%)
Pathologic markers Differentiation
ECE 10 (25.6%) in situ 1 (2.6%)
Positive margins 4 (10.3%) Well 3 (7.7%)
PNI 16 (41.0%) Moderate 18 (46.2%)
LVI 14 (35.9%) Poor 16 (41.0%)
HPV, human papilloma virus; OPSCC, oropharyngeal squamous cell carcinoma; AJCC,
American Joint Commission on Cancer; Tis, tumor stage in situ; ECE, extracapsular
extension; PNI, perineural invasion; LVI, lymphovascular invasion.
Digital image analysis of CD8, FoxP3, CD163, and PD-L1 IHC
was performed employing digital pathology with Aperio software
as previously described (18). CD8 was utilized as a marker
for Teff cells. FoxP3 was utilized as a marker for regulatory T
cells (Tregs). CD163 was utilized as a marker for suppressive
(M2) tumor associated macrophages (TAM). Programmed death
ligand 1 (PD-L1) is highly expressed on cancer cells and some
immune cells in the TME, such as TAMs. Briefly, tissue sections
were scanned on a ScanScopeTM XT at 40x, with an average scan
time of 120 s (compression quality 70). Images were analyzed
using the Color Deconvolution and the Colocalization Aperio
Image Analysis tool. Areas of staining were color separated from
hematoxylin counter-stained sections and the intensity of the
staining was measured on a continuous 0 (bright white) to 255
(black) scale. For each marker, only the cells of highest intensity
staining (digitally scored on a scale of 0–3+) were counted in
the region of interest. Measurements from 5 hpf were taken and
averaged to score each sample. The results are reported as % of
nuclei/cells in a given region of interest with high intensity (3+)
staining.
Statistical Analysis
Linear regression to assess strength of associations between
continuous variables was performed. Significant p-values were
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FIGURE 1 | Consort flow chart for the clinical trial.
considered < 0.05. TUNEL assay results were compared by
multivariable robust linear mixed model with predictors (pre- vs.
post-treatment) and HPV status as well as their interaction. CD8,
FoxP3, CD-163, and PD-L1 IHC intensity was analyzed using
Aperio as described above using a membrane staining algorithm
using linear regression as above. Data were analyzed with R v3.5.0
(R-project.org).
RESULTS
TUNEL Apoptosis Assay
The metformin pre- and post-treatment groups were stratified
and compared by tobacco and HPV status for analysis of
tumor cell apoptosis in the primary tumor samples. Among
these patients, there was a significantly greater increase in
apoptosis with metformin treatment in HPV–, tobacco+
mucosal HNSCC (n = 12, mean 1 13.7/hpf) compared to
HPV+ OPSCC (n = 17, mean 1 5.7/hpf) (p < 0.001)
(Figures 1–3). Number of days treated with metformin for
the two groups was similar (p = 0.92, t-test), with a
mean 13.58 days for the HPV-tobacco+ group (range: 10–
16 days) and a mean 13.71 days for the HPV+ group
(range: 9–24).
Immune Infiltrate in Node Specimens
To analyze the immune TME of the invasive tumor front,
post-treatment lymph node specimens showing ECE were also
compared to archival specimens with ECE. In a previous study,
we demonstrated that the invasive front of lymph nodes with ECE
is histologically similar to the invasive primary tumor front (19).
The nodal samples were used to preserve limited pre-treatment
primary tumor biopsy tissue for possible future analysis. Using
the Aperio digital image analysis software, comparisons of
staining intensity for CD8, FoxP3, CD163, and PD-L1 was made
to quantify percentage of cells staining positive for each marker
in the various compartments in the TME. In both groups, the
CD163, FOXP3, and PD-L1 expression in the perinodal stroma at
the site of invasion were significantly higher compared to regions
with an intact lymph node capsule (p < 0.001) (Figures 4, 5).
Further, these areas were similar at the invasive front between the
metformin and non-metformin groups with respect to CD163
and PD-L1 suggesting that there was no significant change related
to metformin treatment. Most interestingly, CD8 infiltrates were
significantly greater in the tumor stroma at the invasive front
of the metformin group (mean 22.8%) compared to the control
(mean 10.7%) (p = 0.006). Moreover, FoxP3+ Tregs were also
greater in metformin treated group (mean 9%) compared to the
non-metformin treated group (mean 5%) (p= 0.019).
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FIGURE 2 | Tunel assay results: (A,B) show paired samples from an HPV—HNSCC specimen pre- and post-treatment with metformin showing a significant increase
in apoptosis after metformin treatment. (C,D) show paired samples from an HPV+ OPSCC specimen also showing an increase in apoptosis after metformin treatment.
FIGURE 3 | Violin plot for regression analysis of TUNEL data.
DISCUSSION
Here we present novel data on analysis of specimens from
a clinical trial of metformin in HNSCC demonstrating a
significantly increased cancer cell apoptosis in HPV– tobacco+
mucosal HNSCC compared to HPV+ OPSCC tumor samples
after metformin treatment (p < 0.001, Figures 1, 2). This
differential effect on the two tumor types is intriguing, but
of unclear etiology. The mechanism by which metformin may
exert its anticancer effects is not entirely understood, but it is
known to impact cellular metabolism by multiple mechanisms,
including inhibition of mitochondrial complex I, upregulation
of AMP kinase and subsequent regulation of mTOR (20). Thus
the effect on cancers may be attributed to the metabolic impact
on the TME by metformin. In one study, HPV– HNSCC has
been shown to be highly glycolytic, generate large amounts
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FIGURE 4 | IHC for CD8 and FoxP3: (A) non-treated and (B) metformin treated samples stained for CD8 showing higher Teff cell count in the metformin treated
specimens. (C) non-treated and (D) metformin treated specimens stained for FoxP3, showing a higher Treg count in metformin treated specimens.
FIGURE 5 | Violin plot for regression analysis of CD8 and FoxP3 IHC data.
of lactate and have high levels of hypoxia, while HPV+
tumors demonstrated that effective utilization of glycolysis and
oxidative phosphorylation (21). We previously demonstrated
that HNSCC samples with high expression of the lactate
exporter, monocarboxylate transporter 4 (MCT4), staining have
a worse prognosis; high expression of MCT4 correlates with
high glycolysis (22). Taken together, these data suggest differing
metabolism between the two tumor types with higher reliance
on glycolytic metabolism in HPV–, tobacco+ HNSCC. It is
possible that metformin exerts a metabolic strain that is beyond
the tolerance of the already highly glycolytic HPV– tumors. Yet,
further research is required to test this hypothesis. Alternatively,
the anticancer effects of metformin may be indirectly mediated
through effects on other elements of the TME such as enhanced
immune activity as seen in animal models of other tumor
types (12).
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Therefore, we hypothesized that the anticancer effects of
metformin may also be due to an increased anti-tumor immune
response. Dysregulated metabolism in the TME contributes
to immune evasion through various mechanisms including
impairment of tumor infiltrating T cell function, TAM function
and checkpoint inhibition among other mechanisms (23, 24).
Mitigation of this dysregulation in cancer may result in enhanced
immune function. We analyzed specimens for alterations in key
immune elements, including CD8, FoxP3, CD163, and PD-L1.
For this exploratory analysis, we utilized lymph nodes with ECE
as the invasive front at the site of ECE is a point of direct
interaction with the surrounding tissue and stroma (19). We
compared metformin treated specimens to matched archival
specimens without metformin exposure. This group of ECE+
nodal specimens consisted of both HPV+ and HPV– lymph
nodes from the trial, as the individual groups from the trial
were too small to analyze separately. The archival samples were
matched HPV+ and HPV– samples. No significant difference
in PD-L1 or CD163 staining was noted in the cancer or tumor
stroma of samples from patients that had received metformin or
the controls.
However, there was a significant increase in the CD8+ T
cell infiltrate in the tumor stroma at the invasive front in
metformin treated patients compared to archival specimens.
(Figures 4, 5) This finding represents the first clinical data
to point to a link between a metabolic and immune altering
mechanism for metformin. As described above, preclinical data
in an immunocompetent C57BL/6 murine model with syngeneic
MC-38 colon adenocarcinoma and B16 melanoma cancer cells
demonstrates that metformin synergizes with PD-1 inhibition
to substantially increase the antitumor effect of immunotherapy
(12). Metformin inhibited oxygen consumption within the
tumor, resulting in mitigation of hypoxia mediating enhanced
effect of PD-1 inhibition. This preclinical data combined with
evidence of clinical efficacy provides support to explore the
combination of metformin with anticancer immunotherapy in
clinical trials. Further, there is currently a clinical trial underway
in HNSCC to study the impact of metformin on tissue hypoxia
(NCT03510390).
Interestingly, we also identified an increase in FoxP3+ Tregs
in the metformin treated group. This finding was unexpected in
light of the increased CD8+ T cells, as typically Tregs are thought
to be suppressive and thought to inhibit an effective anti-tumor
response (25). However, a recent meta-analysis suggests that in
HPV– HNSCC a higher infiltration of FoxP3+ Tregs correlated
with an improved prognosis (26). There is little data on the effects
of FoxP3+ Tregs in HPV+ OPSCC but there is a trend toward
improved survival with higher infiltrate, and one study showed
evidence that the patients with higher peripheral Treg counts
had a better prognosis (27–29). Recent data based on analysis of
The Cancer Genome Atlas (TCGA) showed that HPV– tumors
are characterized by an immune-poor TME with lower overall
infiltrate and that this finding correlates with a worse prognosis
(30). In contrast HPV+ OPSCC is characterized by an immune
rich TME, which has a better prognosis. An increase in immune
infiltrate may correlate with improved anti-tumor response.
This study has several limitations, including sample size is
limited for both the apoptosis assay and the immune IHC studies,
although statistical significance was reached. The sample size in
this study was too small to determine whether HPV+ OPSCC
or HPV– HNSCC had differential changes in immune infiltrates
for CD8+ Teff or FoxP3+ Tregs. Additionally, we studied
lymph node specimens from subjects receiving metformin and
controls for analysis of the immune markers but the status
of these immune markers is unknown in the primary tumor
specimens. The immune status of the TME of the lymph node
or surrounding soft tissue may differ from that of the primary
tumor; however, we would argue that the data regarding the
immune TME of lymph nodes is also important. Further, studies
must be undertaken to validate these results and to obtain
mechanistic data on how metformin causes increased cancer cell
apoptosis and the increased immune infiltrate and also whether
these two effects are directly linked. Nevertheless, this study does
present intriguing preliminary data directly fromHNSCC clinical
trial samples.
CONCLUSION
Metformin resulted in a greater increase in apoptosis in HPV–
tobacco+ HNSCC than occurred in HPV+ OPSCC. While the
mechanism has yet to be clarified, metformin also appears to alter
the immune TME with an increased infiltrate of CD8+ Teff and
FoxP3 Tregs at the invasive tumor margin of lymph nodes with
ECE.
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